Publication: Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry.
| dc.contributor.author | Zeymer, Uwe | |
| dc.contributor.author | Annemans, Lieven | |
| dc.contributor.author | Danchin, Nicolas | |
| dc.contributor.author | Pocock, Stuart | |
| dc.contributor.author | Newsome, Simon | |
| dc.contributor.author | Van de Werf, Frans | |
| dc.contributor.author | Medina, Jesús | |
| dc.contributor.author | Bueno, Hector | |
| dc.date.accessioned | 2020-10-29T14:15:24Z | |
| dc.date.available | 2020-10-29T14:15:24Z | |
| dc.date.issued | 2019-03 | |
| dc.description.abstract | Atrial fibrillation (AF) is associated with increased morbidity in acute coronary syndrome patients, but impact on outcomes beyond 1 year is unclear. This was a post-hoc analysis from the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry (NCT01171404), a prospective, observational study conducted in Europe and Latin America, which enrolled acute coronary syndrome survivors at discharge. Antithrombotic management patterns, mortality, a composite endpoint of death/new non-fatal myocardial infarction/stroke and bleeding events were assessed after 2 years of follow-up in patients with or without AF. Of 10,568 patients enrolled, 397 (4.7%) had prior AF and 382 (3.6%) new-onset AF during index hospitalisation. Fewer patients with AF underwent percutaneous coronary intervention (52.1% vs. 66.6%; P<0.0001). At discharge, fewer AF patients received dual antiplatelet therapy (71.6% vs. 89.5%; P<0.0001); oral anticoagulant use was higher in AF patients but was still infrequent (35.0% vs. 2.5%; P<0.0001). Use of dual antiplatelet therapy and oral anticoagulants declined over follow-up with over 50% of all AF/no AF patients remaining on dual antiplatelet therapy (55.6% vs. 60.6%), and 23.3% (new-onset AF) to 42.1% (prior AF) on oral anticoagulants at 2 years. At 2 years, mortality, composite endpoint and bleeding rates were higher in AF patients (all P<0.0001) compared to patients without AF. On multivariable analysis, the risk of mortality or the composite endpoint was significant for prior AF ( P=0.003, P=0.001) but not new-onset AF ( P=0.88, P=0.92). Acute coronary syndrome patients with AF represent a high-risk group with increased event rates during long-term follow-up. Prior AF is an independent predictor of mortality and/or ischaemic events at 2 years. Use of anticoagulants in AF after acute coronary syndrome is still suboptimal. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: EPICOR was funded by AstraZeneca | es_ES |
| dc.format.number | 2 | es_ES |
| dc.format.page | 121-129 | es_ES |
| dc.format.volume | 8 | es_ES |
| dc.identifier.citation | Eur Heart J Acute Cardiovasc Care. 2019; 8(2):121-129 | es_ES |
| dc.identifier.doi | 10.1177/2048872618769057 | es_ES |
| dc.identifier.journal | European heart journal. Acute cardiovascular care | es_ES |
| dc.identifier.pubmedID | 29611427 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/11261 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | SAGE Publishing | es_ES |
| dc.relation.publisherversion | https://doi.org/10.1177/2048872618769057 | es_ES |
| dc.repisalud.institucion | CNIC | es_ES |
| dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinaria | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject.mesh | Registries | es_ES |
| dc.subject.mesh | Acute Coronary Syndrome | es_ES |
| dc.subject.mesh | Aged | es_ES |
| dc.subject.mesh | Atrial Fibrillation | es_ES |
| dc.subject.mesh | Cause of Death | es_ES |
| dc.subject.mesh | Europe | es_ES |
| dc.subject.mesh | Female | es_ES |
| dc.subject.mesh | Fibrinolytic Agents | es_ES |
| dc.subject.mesh | Follow-Up Studies | es_ES |
| dc.subject.mesh | Humans | es_ES |
| dc.subject.mesh | Incidence | es_ES |
| dc.subject.mesh | Latin America | es_ES |
| dc.subject.mesh | Male | es_ES |
| dc.subject.mesh | Middle Aged | es_ES |
| dc.subject.mesh | Percutaneous Coronary Intervention | es_ES |
| dc.subject.mesh | Prognosis | es_ES |
| dc.subject.mesh | Prospective Studies | es_ES |
| dc.subject.mesh | Risk Factors | es_ES |
| dc.subject.mesh | Survival Rate | es_ES |
| dc.subject.mesh | Thrombolytic Therapy | es_ES |
| dc.subject.mesh | Thrombosis | es_ES |
| dc.subject.mesh | Time Factors | es_ES |
| dc.title | Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. | es_ES |
| dc.type | journal article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | ee6666ff-4064-47e5-9144-afdcc607733b | |
| relation.isAuthorOfPublication | 4e417023-fc1f-41d2-8130-485f76466465 | |
| relation.isAuthorOfPublication.latestForDiscovery | ee6666ff-4064-47e5-9144-afdcc607733b |


